Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries.
Amgen, Inc.’s KRAS G12C inhibitor sotorasib is showing similar benefit in Phase II in third-line non-small cell lung cancer (NSCLC) as was seen in Phase I, and analysts expect it will be enough to gain accelerated approval from the US Food and Drug Administration.
Amgen said the results of its Phase II CodeBreak 100 clinical trial in previously treated NSCLC were positive back in...
Create an account to read this article
Already a subscriber?
Lynkuet will compete with Astellas's Veozah/Veoza
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
